Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra, Inc. (NYSE: PEN) is described in its public communications as the world’s leading thrombectomy company, with a portfolio focused on computer assisted vacuum thrombectomy (CAVT™) and related devices for serious vascular and neurovascular conditions. The Penumbra news feed on this page aggregates company announcements, clinical trial updates and capital markets communications that shape how investors and clinicians follow the PEN stock story.
Recent news includes the announcement of a definitive Agreement and Plan of Merger with Boston Scientific Corporation, under which a Boston Scientific subsidiary will merge with and into Penumbra, leaving Penumbra as a wholly owned subsidiary if the transaction closes. The joint press release details the planned cash-and-stock consideration and notes that, upon completion, Penumbra’s securities are expected to be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934.
Beyond M&A developments, Penumbra’s news flow features earnings releases and preliminary financial updates furnished via Form 8-K, outlining revenue trends, margins and non-GAAP measures such as constant currency revenue and adjusted EBITDA. These items provide context on the company’s operating performance and financial outlook as it continues to develop and commercialize thrombectomy and embolization technologies.
Penumbra also issues news around clinical research milestones. Notable examples include results from the pivotal STORM-PE randomized controlled trial, which evaluated CAVT using Penumbra’s Lightning Flash™ plus anticoagulation versus anticoagulation alone in acute intermediate-high risk pulmonary embolism. Company press releases describe superior reductions in right heart strain, thrombus burden and improvements in functional outcomes for patients treated with CAVT plus anticoagulation, with comparable safety profiles between treatment arms.
Additional news items cover leadership changes and investor relations activities, such as the appointment of a new company president and scheduled presentations at healthcare and investor conferences, including the J.P. Morgan Healthcare Conference and other sector events. These updates highlight how Penumbra’s management communicates with the investment community and discusses its clinical and commercial strategy.
By following this PEN news page, readers can review a consolidated stream of Penumbra’s press releases, transaction announcements, clinical trial disclosures and financial updates, all of which are sourced from official company communications and SEC-related materials.
Penumbra, Inc. (NYSE: PEN) has announced a partnership with RapidAI to enhance clinical decision-making for pulmonary embolism (PE) diagnosis. This collaboration aims to develop AI-driven modules that streamline triage and improve the interpretation of CT scans. The initiative is timely, considering the challenges posed by the COVID-19 pandemic. Penumbra's Indigo® System, recently launched for blood clot removal, aligns with its commitment to addressing unmet clinical needs. The partnership is expected to increase awareness and treatment options for PE, a critical healthcare issue.
Penumbra, Inc. (NYSE: PEN) announced its participation in the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 1:30 PM ET (10:30 AM PT). The event will showcase the company's innovative healthcare solutions. Interested parties can access a webcast of the presentation through the company's website, available for two weeks post-event. Penumbra specializes in designing and market-leading products for challenging medical conditions, primarily serving U.S., Europe, Canada, and Australia.
Penumbra, Inc. (NYSE: PEN) reported third-quarter 2020 financials, revealing a revenue increase of 8.3% to $151.1 million compared to the same period in 2019. US revenue surged 22% to $109.7 million. However, neuro product sales declined by 8.8%, totaling $75.9 million, while vascular product sales rose 33.6% to $75.2 million. Operating loss stood at $20.2 million, impacted by one-time personnel expenses related to the Lightning product launch. The ongoing COVID-19 pandemic continues to create uncertainty in business performance.
Penumbra, Inc. (NYSE: PEN) will hold a conference call on October 28, 2020, at 4:30 PM ET to discuss its Q3 2020 financial results. The call will occur after market close, and a press release with the financial results will be available at that time. This initiative highlights Penumbra's support for democracy by designating Election Day 2020 as a paid holiday for U.S. employees. Investors can access the call by phone or via a webcast on the company’s website.
Penumbra, Inc. (NYSE: PEN) announced that its management will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 17, 2020, at 10:15 AM EDT. The event will be accessible via a webcast on the company's investor website, available for two weeks post-event. Penumbra, headquartered in Alameda, California, specializes in innovative healthcare solutions, selling products to hospitals in the U.S., Europe, Canada, and Australia, among other regions.
Penumbra, Inc. (NYSE: PEN) announced its participation in the Wells Fargo 2020 Virtual Healthcare Conference on September 9, 2020, at 3:20 PM EDT. The presentation will showcase Penumbra's innovative healthcare solutions.
Investors can access the webcast on the company's website and it will be available for two weeks after the event. Penumbra is focused on developing and marketing advanced therapies for medical conditions, primarily selling its products in the U.S., Europe, Canada, and Australia.
Penumbra, Inc. (NYSE: PEN) reported a 21.7% decline in revenues to $105.1 million for Q2 2020 compared to Q2 2019. US revenue reached $78.0 million, down approximately 10% year-over-year. The company's gross profit was $64.9 million, reflecting a margin decrease to 61.8%. Total operating expenses rose to $82.6 million, leading to an operating loss of $17.6 million. The COVID-19 pandemic continues to impact business operations, and the company cannot reliably estimate future effects.
Penumbra, Inc. (NYSE: PEN) will present at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 3:30 PM EDT. The presentation will be available via webcast through the company’s investor section on its website, accessible for two weeks post-event. Based in Alameda, California, Penumbra focuses on innovative therapies across healthcare, targeting significant medical needs and selling products mainly in the U.S., Europe, Canada, and Australia.
Penumbra, Inc. (NYSE: PEN) has announced a conference call scheduled for August 3, 2020, at 4:30 PM ET to discuss its financial results for the second quarter of 2020. A press release detailing the financial results will be issued after market close on the same day. The conference call can be accessed by phone or via webcast on the company’s website. Penumbra is a global healthcare company focused on innovative therapies and sells its products to hospitals and healthcare providers primarily through a direct sales organization.
FAQ
What is the current stock price of Penumbra (PEN)?
What is the market cap of Penumbra (PEN)?
